Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin

por Kelly, Ronan J, Lopez-Chavez, Ariel, Citrin, Deborah, Janik, John E, Morris, John C
Publicado 2011

Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma

por Moiseyenko, Andrey, Muggia, Franco, Condamine, Thomas, Pulini, Jennifer, Janik, John E., Cho, Daniel C.
Publicado 2020

Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)

por Burbelo, Peter D, Meoli, Elise, Leahy, Hannah P, Graham, Jhanelle, Yao, Karen, Oh, Unsong, Janik, John E, Mahieux, Renaud, Kashanchi, Fatah, Iadarola, Michael J, Jacobson, Steven
Publicado 2008

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

por Davis, Elizabeth J, Martin-Liberal, Juan, Kristeleit, Rebecca, Cho, Daniel C, Blagden, Sarah P, Berthold, Dominik, Cardin, Dana B, Vieito, Maria, Miller, Rowan E, Hari Dass, Prashanth, Orcurto, Angela, Spencer, Kristen, Janik, John E, Clark, Jason, Condamine, Thomas, Pulini, Jennifer, Chen, Xuejun, Mehnert, Janice M
Publicado 2022

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

por Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N., Jay Ramsey, W., Kennedy, Eugene, Mautino, Mario R., Link, Charles J., Lin, Ray S., Royer-Joo, Stephanie, Liang, Xiaorong, Salphati, Laurent, Morrissey, Kari M., Mahrus, Sami, McCall, Bruce, Pirzkall, Andrea, Munn, David H., Janik, John E., Khleif, Samir N.
Publicado 2018